Teachers Advisors LLC decreased its holdings in shares of Laboratory Corporation of America Holdings (NYSE:LH) by 8.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 406,999 shares of the medical research company’s stock after selling 38,373 shares during the quarter. Teachers Advisors LLC owned about 0.40% of Laboratory Corporation of America Holdings worth $62,735,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of LH. Raymond James Trust N.A. boosted its stake in Laboratory Corporation of America Holdings by 5.0% during the 2nd quarter. Raymond James Trust N.A. now owns 3,271 shares of the medical research company’s stock worth $504,000 after acquiring an additional 156 shares during the last quarter. Summit Global Investments boosted its stake in Laboratory Corporation of America Holdings by 328.6% during the 2nd quarter. Summit Global Investments now owns 42,264 shares of the medical research company’s stock worth $6,515,000 after acquiring an additional 32,402 shares during the last quarter. AJO LP boosted its stake in Laboratory Corporation of America Holdings by 69.4% during the 2nd quarter. AJO LP now owns 483,627 shares of the medical research company’s stock worth $74,546,000 after acquiring an additional 198,100 shares during the last quarter. Financial Counselors Inc. boosted its stake in Laboratory Corporation of America Holdings by 5.9% during the 2nd quarter. Financial Counselors Inc. now owns 1,641 shares of the medical research company’s stock worth $253,000 after acquiring an additional 92 shares during the last quarter. Finally, Aberdeen Asset Management PLC UK boosted its stake in Laboratory Corporation of America Holdings by 26.2% during the 2nd quarter. Aberdeen Asset Management PLC UK now owns 32,423 shares of the medical research company’s stock worth $4,998,000 after acquiring an additional 6,740 shares during the last quarter. Institutional investors own 93.21% of the company’s stock.

Several research firms recently weighed in on LH. Zacks Investment Research raised shares of Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a research note on Thursday, July 27th. Craig Hallum reissued a “buy” rating and set a $179.00 price objective (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Thursday, July 27th. Barclays PLC lifted their price objective on shares of Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a research note on Thursday, July 27th. Jefferies Group LLC reissued a “hold” rating and set a $170.00 price objective (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Wednesday. Finally, ValuEngine raised shares of Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a research note on Wednesday, September 6th. Five equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $164.00.

Laboratory Corporation of America Holdings (NYSE LH) opened at 153.60 on Friday. Laboratory Corporation of America Holdings has a 52 week low of $119.51 and a 52 week high of $164.22. The firm has a 50-day moving average of $156.60 and a 200-day moving average of $147.65. The company has a market cap of $15.64 billion, a price-to-earnings ratio of 21.51 and a beta of 0.94.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.40 by $0.07. The company had revenue of $2.50 billion during the quarter, compared to the consensus estimate of $2.47 billion. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The company’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.36 EPS. Equities analysts forecast that Laboratory Corporation of America Holdings will post $9.54 earnings per share for the current year.

In related news, CFO Glenn A. Eisenberg sold 5,968 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $159.46, for a total value of $951,657.28. Following the transaction, the chief financial officer now directly owns 18,122 shares in the company, valued at approximately $2,889,734.12. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director R Sanders Williams sold 3,100 shares of the stock in a transaction on Friday, August 11th. The stock was sold at an average price of $156.88, for a total value of $486,328.00. Following the completion of the transaction, the director now owns 10,073 shares in the company, valued at $1,580,252.24. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 222,968 shares of company stock valued at $34,980,922. Insiders own 0.90% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/16/teachers-advisors-llc-has-62-74-million-stake-in-laboratory-corporation-of-america-holdings-lh.html.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Stock Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related stocks with our FREE daily email newsletter.